Ann: SCENESSE in DNA Repair, page-6

Good news especially for those with the condition. It's another example of CUV getting on with the program albeit a little slower than we would like. I expected this to happen in Japan where there is around 50 times the prevalence vs USA. Perhaps there is something delaying the progress of getting the approvals in Australia and Japan for EPP so they moved on anyway. Of course the wider implication is that positive findings will be monumental because they would be adaptive to all those in the general population who could be candidates for skin cancers -Huge numbers in NZ, Australia , USA etc. I hope the sales for EPP in the USA are quite significant in the October quarterly and this should give impetus to the share price before the AGM. GLTA